| __timestamp | Alnylam Pharmaceuticals, Inc. | Iovance Biotherapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 9335772 |
| Thursday, January 1, 2015 | 60610000 | 12390000 |
| Friday, January 1, 2016 | 89354000 | 25602000 |
| Sunday, January 1, 2017 | 199365000 | 21262000 |
| Monday, January 1, 2018 | 382359000 | 28430000 |
| Tuesday, January 1, 2019 | 479005000 | 40849000 |
| Wednesday, January 1, 2020 | 588420000 | 60210000 |
| Friday, January 1, 2021 | 620639000 | 83664000 |
| Saturday, January 1, 2022 | 770658000 | 104097000 |
| Sunday, January 1, 2023 | 795646000 | 106916000 |
| Monday, January 1, 2024 | 975526000 |
Data in motion
In the competitive landscape of biotechnology, operational efficiency is paramount. Over the past decade, Alnylam Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc. have demonstrated contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. Alnylam's SG&A costs have surged by over 1,600% from 2014 to 2023, reflecting its aggressive expansion and strategic investments. In contrast, Iovance's expenses have grown by approximately 1,000%, indicating a more measured approach.
These trends highlight the diverse strategies employed by biotech firms in managing operational costs, crucial for sustaining innovation and market presence.
Cost Management Insights: SG&A Expenses for Merck & Co., Inc. and Alnylam Pharmaceuticals, Inc.
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Pharming Group N.V. Trends and Insights
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc.
Alnylam Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Dynavax Technologies Corporation Trends and Insights
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Novavax, Inc.
Breaking Down SG&A Expenses: Teva Pharmaceutical Industries Limited vs Iovance Biotherapeutics, Inc.
Neurocrine Biosciences, Inc. and Iovance Biotherapeutics, Inc.: SG&A Spending Patterns Compared
BioMarin Pharmaceutical Inc. and Iovance Biotherapeutics, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Who Optimizes SG&A Costs Better? Arrowhead Pharmaceuticals, Inc. or Iovance Biotherapeutics, Inc.
Mesoblast Limited or Iovance Biotherapeutics, Inc.: Who Manages SG&A Costs Better?